Authors: Bhatt G∗, Maddocks K∗ Christian B∗
Published in: Curr Hematol Malig Rep. 2016 Sep 9.
Evolution of cancer therapeutics has resulted in the development of agents with varying mechanisms of selective target inhibition.
One such therapeutic approach is utilizing antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic agent in order to maximize efficacy with fewer toxicities.
This review focuses on CD30 as a therapeutic target and the development and clinical activity of the ADC brentuximab vedotin in Hodgkin lymphoma (HL) and other B cell lymphomas.
Author affiliation: The Ohio State University James Comprehensive Cancer Center, 420 West 10th Avenue, A348 Starling Loving Hall, Columbus, OH, 43210, USA.
Featured Image: Micrograph of Hodgkin lymphoma. Lymph node FNA specimen. Field stain. The micrograph shows a mixture of cells common in Hodgkin Lymphoma, including Eosinophils, Reed-Sternberg cells, Plasma cells and Histiocytes. Feature image Courtesy: Nephron. This file is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license. CC BY-SA 3.0